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Introduction: The MRE11A-RAD50-Nibrin (MRN) complex plays several critical roles related to repair of DNA
double-strand breaks. Inherited mutations in the three components predispose to genetic instability disorders and
the MRN genes have been implicated in breast cancer susceptibility, but the underlying data are not entirely
convincing. Here, we address two related questions: (1) are some rare MRN variants intermediate-risk breast cancer
susceptibility alleles, and if so (2) do the MRN genes follow a BRCA1/BRCA2 pattern wherein most susceptibility
alleles are protein-truncating variants, or do they follow an ATM/CHEK2 pattern wherein half or more of the
susceptibility alleles are missense substitutions?
Methods: Using high-resolution melt curve analysis followed by Sanger sequencing, we mutation screened the
coding exons and proximal splice junction regions of the MRN genes in 1,313 early-onset breast cancer cases and
1,123 population controls. Rare variants in the three genes were pooled using bioinformatics methods similar to
those previously applied to ATM, BRCA1, BRCA2, and CHEK2, and then assessed by logistic regression.
Results: Re-analysis of our ATM, BRCA1, and BRCA2 mutation screening data revealed that these genes do not
harbor pathogenic alleles (other than modest-risk SNPs) with minor allele frequencies >0.1% in Caucasian
Americans, African Americans, or East Asians. Limiting our MRN analyses to variants with allele frequencies of <0.1%
and combining protein-truncating variants, likely spliceogenic variants, and key functional domain rare missense
substitutions, we found significant evidence that the MRN genes are indeed intermediate-risk breast cancer
susceptibility genes (odds ratio (OR) = 2.88, P = 0.0090). Key domain missense substitutions were more frequent than
the truncating variants (24 versus 12 observations) and conferred a slightly higher OR (3.07 versus 2.61) with a lower
P value (0.029 versus 0.14).
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Conclusions: These data establish that MRE11A, RAD50, and NBN are intermediate-risk breast cancer susceptibility
genes. Like ATM and CHEK2, their spectrum of pathogenic variants includes a relatively high proportion of missense
substitutions. However, the data neither establish whether variants in each of the three genes are best evaluated
under the same analysis model nor achieve clinically actionable classification of individual variants observed in this
study.Introduction
Based on risk and frequency, three classes of breast cancer
susceptibility genes or loci are currently recognized: high-
risk genes such as BRCA1 and BRCA2 (Mendelian Inher-
itance in Man numbers (MIMs) 113705 and 600185) in
which protein-truncating mutations and severely dysfunc-
tional missense substitutions confer a five- to ten-fold in-
creased risk and for which the summed allele frequency in
the general population is <1%; intermediate-risk genes
such at ATM and CHEK2 (MIMs 208900 and 604373) in
which protein-truncating mutations and severely dysfunc-
tional missense substitutions confer a two- to five-fold in-
creased risk and for which the summed allele frequency
in the general population may approach 1%; and com-
mon, modest-risk single nucleotide polymorphisms (SNPs)
which individually have much higher frequency but only
rarely confer risk greater than 1.25-fold [1,2]. Linkage ana-
lysis provided an effective genome-wide approach for
locating high-risk susceptibility genes, and genome-
wide association study provided an effective approach for
finding risk-associated SNPs. While exome sequencing-
based strategies may eventually provide a hypothesis-free,
genome-wide approach for identification of intermediate-
risk genes, much of our current knowledge base has flo-
wed from candidate gene studies [3].
The MRN complex, formed from dimers of the pro-
teins encoded by MRE11A, RAD50, and NBN (MIMs
600814, 604040, and 602667), plays key roles in DNA
double-strand break (DSB) repair, meiotic recombination,
cell cycle checkpoints, and maintenance of telomeres [4].
In mice, homozygous knockouts of these genes are lethal
[5-7]. Humans born with biallelic mutations in any one of
the three genes share a cellular phenotype that includes
sensitivity to ionizing radiation, a deficit in DNA DSB re-
pair, and chromosomal instability (MIM 604391; MIM
251260) [8]. Moreover, these people are at risk of severe
cancer susceptibility phenotypes. For example, two broth-
ers who were compound heterozygotes for mutations that
fell in the amino region of the MRE11A protein died of
pulmonary adenocarcinoma before age 20 [9,10], which
would seem very unlikely in the absence of an underlying
cancer predisposition. Susceptibility to lymphoma is a
prominent feature of Nijmegen breakage syndrome, which
is caused by biallelic mutation of NBN [11]. While too
few human biallelic RAD50 mutation carriers have beenidentified to reach a conclusion about their cancer suscep-
tibility, more than 20% of mice homozygous for a hypo-
morphic Rad50 allele (Rad50 p.Lys22Met) that lived past
age four months died with lymphoma or leukemia [12].
Breast cancer risks for heterozygous carriers of MRN
gene mutations were summarized briefly by Hollestelle
et al. [3]. Of the three genes, NBN has the strongest evi-
dence in support of acting as an intermediate-risk breast
cancer gene. This is largely because the truncating vari-
ant NBN c.657del5 has a high enough frequency among
individuals of Slavic origin to be evaluated by case-
control analysis, and meta-analysis of nine such studies
revealed a combined odds ratio (OR) of 2.63 (95% confi-
dence interval (CI) 1.76 to 3.93) for this variant [13].
Most evidence in favor of RAD50 rested on a truncating
variant RAD50 c.687delT which has been observed in
Finnish cases and controls [14,15]; while subsequent
studies in the same and other populations are consistent
with the hypothesis that RAD50 is an intermediate-risk
breast or pancreatic cancer susceptibility gene, they have
not provided significant supporting evidence [16,17].
Evidence for MRE11A rests primarily on the observation
of two mutations in the gene from a series of eight non-
BRCA1/2 breast cancer families with tumors that showed
loss of all three MRN proteins [18].
Previously, we performed case-control mutation scree-
ning studies of ATM, CHEK2, XRCC2, and RAD51 to
clarify our understanding of their role in breast cancer
susceptibility [19-22]. A common thread across these
studies has been use of bioinformatic and statistical ap-
proaches designed to detect evidence of pathogenicity
from both truncating and splice junction variants (T +
SJV) and/or rare missense substitutions (rMS). Here, we
apply a case-control mutation screening strategy in an
ethnically diverse series of subjects to evaluate MRE11A,
RAD50, and NBN. Given that the three proteins form an
evolutionarily conserved complex involved in mainten-
ance of genomic integrity, we decided to evaluate the
three genes as a single large candidate intermediate-risk
breast cancer susceptibility gene with a concatenated
open reading frame of 2,774 amino acids - which never-
theless is not quite as large as the 3,056 amino acid open
reading frame of ATM. Our analysis addresses two related
questions: (1) are some rare MRN variants intermediate-
risk breast cancer susceptibility alleles, and if so (2) do the
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ceptibility alleles are protein-truncating variants, or do
they follow an ATM/CHEK2 pattern wherein half or more
of the susceptibility alleles are missense substitutions?
Methods
Study sample
The design for this study has been described in detail
previously [19,20,22]. Briefly, eligible participants inclu-
ded women ascertained by population-based sampling
by the Australian, Northern California, and Ontario sites
of the Breast Cancer Family Registry (BCFR) [23]. Sub-
jects were recruited between 1995 and 2005. Selection
criteria for cases (N = 1,313) were diagnosis of breast
cancer at or before age 45 years and self-reported race/
ethnicity plus grandparents’ country of origin informa-
tion consistent with Caucasian, East Asian, Hispanic/
Latino, or African American racial/ethnic heritage. The
controls (N = 1,123) were frequency matched to the cases
within each center on racial/ethnic group, with age at se-
lection not more than ± 10 years from the age range at
diagnosis of the cases gathered from the same center. Be-
cause of the shortage of available controls in some racial/
ethnic and age groups, the frequency matching was not
one-to-one in all subgroups.
Recruitment and genetic studies were approved by the
Ethics Committee of the International Agency for Re-
search on Cancer (IARC), the University of Utah Insti-
tutional Review Board (IRB), and the local IRBs of the
BCFR centers from which we received samples. These
local IRBs were the Health Sciences Human Research
Ethics Subcommittee of the University of Melbourne,
Australia; the Institutional Review Board of the Cancer
Prevention Institute of California; and the Research Ethics
Boards of Mount Sinai Hospital and the University Health
Network, Ontario, Canada. Written informed consent was
obtained from each participant.
Mutation screening
For mutation screening of the coding exons and prox-
imal splice junction regions of MRE11A (NM_005591.3),
RAD50 (NM_005732.3) and NBN (NM_002485.4), we
used 30 ng of whole-genome amplified (WGA) DNA ob-
tained by mixing 15 ng of amplified DNA from each of
two independent WGA reactions. The laboratory pro-
cess was as described in detail for our recent studies of
ATM, CHEK2, XRCC2, and RAD51 [19-22]. Our semi-
automated approach, handled by a Laboratory Infor-
mation Management System (LIMS) [24,25], relies on
mutation scanning by high-resolution melt curve (HRM)
analysis followed by direct Sanger sequencing of the in-
dividual samples for which an aberrant melting curve pro-
file is indicative of the presence of a sequence variant. In a
previous work, we showed that the HRM techniqueshowed high sensitivity and specificity (1.0, and 0.8, re-
spectively, for amplicons of <400 bp) for mutation screen-
ing by comparing the results with those obtained with
Sanger sequencing [26].
For MRN amplicons harboring a SNP(s) with fre-
quency ≥1% in either dbSNP or initial amplicon testing,
we applied a simultaneous mutation scanning and geno-
typing approach using HRM analysis to improve the sen-
sitivity and the efficiency of the mutation screening, as
described previously [24,25].
All exonic sequence variants, plus intronic sequence
variants that fell within 20 bp of a splice acceptor or
eight bp of a splice donor, and were either unreported or
had an allele frequency of <1% in the large scale refer-
ence groups ‘Caucasian Americans’, ‘African Americans’
and ‘East Asians’ based on exome variant server (EVS)
and 1,000 genomes project (1000G) data [27,28], were
confirmed either by independent re-amplification and
sequencing from each of the two independent WGA re-
action products and concordant variant calls, or, for five
variants, by re-amplification and sequencing from ge-
nomic DNA.
All samples that failed either at the primary PCR,
secondary PCR, or sequencing reaction stage were re-
amplified from WGA DNAs or genomic DNAs. Samples
that still did not provide satisfactory mutation screening
results for at least 80% of the concatenated MRN coding
sequence were excluded from further analysis. Primer
and probe sequences are available from the authors upon
request.
Alignments and scoring of missense substitutions
We used M-Coffee [29], which is part of the Tree-based
consistency objective function for alignment evaluation
(T-Coffee) software suite of alignment tools [30] to pre-
pare a protein multiple sequence alignment for each of
the three MRN proteins (MRE11A, RAD50 and NBN) in
order to predict the effect of missense substitutions on
the proteins and on the activity of the MRN complex.
Each alignment consisted of sequences from 16 species:
Homo sapiens, Macaca mulatta, Callithrix jacchus, Mus
musculus, either Sus scrofa or Bos Taurus, Loxodonta
africana, Dasypus novemcinctus, Monodelphis domestica,
Ornithorhynchus anatinus, Gallus gallus, Anolis caroli-
nensis, either Xenopus tropicalis or Xenopus laevis, Lati-
meria chalumnae, either Fugu rubripes or Danio rerio,
Branchiostoma lanceolatum, and Strongylocentrotus pur-
puratus. The alignments were characterized using the
Protpars routine of Phylogeny Inference Package version
3.2 software (PHYLIP) [31] to make a maximum parsi-
mony estimate of the number of substitutions that oc-
curred along each clade of the underlying phylogeny.
The sequence alignment, or updated versions thereof, is
available at the Align Grantham variation Grantham
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tutions observed during our mutation screening of the
three MRN genes were scored using the Align-GVGD
and Sorting Intolerant from Tolerant (SIFT) software
programs with our curated alignments, and with poly-
morphism phenotyper (PolyPhen-2.1) software using its
precompiled alignments [33-35]. In brief, Align-GVGD
grades missense substitutions against a protein multiple
sequence alignment based on a combination of Gran-
tham Variation (GV), which measures the amount of
physicochemical variation at a particular position in the
alignment, and Grantham Deviation (GD), which mea-
sures the physicochemical difference between the mis-
sense residue and the range of variation observed at its
position in the protein. The classifier provides seven or-
dered grades (C65, C55, C45, C35, C25, C15 and C0)
ranging from the most likely deleterious to least likely
deleterious [33]. SIFT is a sequence homology-based
tool that predicts variants in the query sequence as ‘tol-
erated’ or ‘deleterious’ using normalized probabilities
calculated from the input multiple sequence alignment
[34]. Variants at a position with normalized probabilities
less than 0.05 are predicted deleterious and predicted
neutral with a probability greater than or equal to 0.05.
PolyPhen-2 predicts variants as ‘benign’, ‘possibly dam-
aging’, or ‘probably damaging’ based on eight sequence-
based and three structure-based predictive features [35].
The alignment pipeline used in PolyPhen-2 selects ho-
mologous sequences using a clustering algorithm and
then constructs and refines the alignment yielding an
alignment containing both orthologs and paralogs that
may or may not be full length, which yields a wider
breadth of sequences but decreased depth compared
with the curated alignments used with Align-GVGD
and SIFT [36].
In silico prediction on splicing
Sequence variants falling in the first three bp or last
three bp of an exon, plus intronic variants detected in
the vicinity of the splice junction sequences, with allele
frequencies <1%, were scored for their potential impact
on splicing using MaxEntScan (MES), which computes
the maximum entropy score of a given sequence using
splice site models trained on human data [37]. In work
to be published elsewhere, we calibrated MES by calcu-
lating the average and standard deviation of MES scores
for the wild-type splice junctions in BRCA1, BRCA2,
and ATM, allowing us to convert raw MES scores into z-
scores. Based on BRCA1 and BRCA2 mutation screening
data used previously to calibrate Align-GVGD [33,38],
we found that rare variants that fall within the acceptor
or donor region and reduce the MES score for the splice
signal in which they fall show an approximately 95%
probability to damage splice junction function when theyresult in a calibrated MES score of z < −2, or approxi-
mately 40% probability when they result in a calibrated
MES score of −2 < z ≤ −1 [39]; Vallee et al., manuscript
in preparation. Thus these MES-based rules were used
to identify rare sequence variants that are likely to alter
MRN gene mRNA splicing.
Analysis of rare variant threshold frequency from ATM,
BRCA1, BRCA2, and CHEK2 data
For ATM, we examined the relationship between sequence
variant frequency and breast cancer risk as follows. Fre-
quencies for all of the variants included in our 2009 ATM
case-control mutation screening meta-analysis [19] were
extracted from the EVS (for Caucasian American and
African American frequencies) or UK National Genetics
Reference Laboratory Manchester (NGRL Manchester)
summary of 1000G data (for East Asian allele frequencies)
[40]. T + SJV (as defined in [19]) plus missense substi-
tutions and in-frame indels falling from position 1960
through the end of the protein were then grouped into the
following allele frequency bins: 1% to 0.32%, 0.32% to
0.10%, 0.10% to 0.032%, <0.032%. ORs for each bin were
then estimated by logistic regression, adjusting for study,
ethnicity and mutation-screening method employed, using
Stata version 11 software (StataCorp, College Station, TX,
USA).
CHEK2 sequence variants included in our 2011 CHEK2
case-control mutation screening study [20] were evaluated
in the same way except that (a) position in the protein was
not considered, and (b) logistic regressions were adjusted
for study center and race/ethnicity.
For BRCA1 and BRCA2, we examined the relationship
between frequency and risk as follows. First we defined
‘pseudo-cases’ and ‘pseudo-controls’ from the tested
population at Myriad Genetics in the data set we used to
evaluate more than 1,000 BRCA1/2 sequence variants in
2007 [38]. The data set included results from appro-
ximately 68,000 full-sequence tests. Pseudo-cases for
BRCA1 were defined to be all tested individuals who
were affected with breast cancer and were not found to
carry a pathogenic variant in either BRCA1 or BRCA2;
pseudo-controls were taken to be affected individuals
who were found to carry pathogenic mutations in BRCA2
(thus explaining their personal and family history of
cancer). A similar approach was taken for BRCA2 var-
iants, with carriers of BRCA1 pathogenic variants ser-
ving as pseudo-controls. For each gene, variants were
categorized into frequency bins as described above. Lo-
gistic regression was then used to estimate ORs for each
frequency bin. Note that, because carriage of clearly patho-
genic variants was used to differentiate between pseudo-
cases and pseudo-controls, the BRCA1 and BRCA2 ORs
were estimated from the distributions of unclassified
variants.
Table 1 Distribution of cases and controls by age, race or
ethnicity, and study center†
Distributions Cases, n (%) Controls, n (%)
Age range, yr
≤30 108 (8.2%) 67 (6.0%)
31-35 325 (24.8%) 172 (15.3%)
36-40 436 (33.2%) 237 (21.1%)
41-45 443 (33.8%) 203 (18.1%)
46-50 0 (0.0%) 230 (20.5%)
51-55 0 (0.0%) 212 (18.9%)
Total 1,312 (100.0%) 1,121 (100.0%)
Race or ethnicity
Caucasian 848 (64.6%) 967 (86.3%)
East Asian 208 (15.9%) 71 (6.3%)
Latina 158 (12.0%) 47 (4.2%)
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ing data
To assess the relationship between MRN variants and
breast cancer risk, analyses were performed using the
chi-square test and multivariable unconditional logistic
regression using Stata version 11 software (StataCorp).
Differences in the case-control ratio between racial/eth-
nic groups and study center were accounted for by in-
cluding categorical variables for each racial/ethnic group
and each study center. Adjustment for racial/ethnic group
should also capture confounding of genetic and social fac-
tors with interaction terms, allowing that this confounding
effect may be different for the broadly labeled racial/ethnic
groups in different centers. P values reported from ana-
lyses of the MRN case-control data are from the likelihood
ratio test, adjusted for racial/ethnic group and study cen-
ter, unless otherwise noted.Recent African Ancestry 98 (7.5%) 36 (3.2%)
Total 1,312 (100.0%) 1,121 (100.0%)
Study center
BCFR-Australia 593 (45.2%) 522 (46.6%)
BCFR-Canada 302 (23.0%) 463 (41.3%)
BCFR-Northern California 417 (31.8%) 136 (12.1%)
Total 1,312 (100.0%) 1,121 (100.0%)
†The three subjects excluded because of poor mutation-screening performance
are not included; percentage data are the percentages of the total number of
patient or control DNA in the category indicated that met the mutation-Results
Number of subjects included in the analysis
Of the 2,436 BCFR participants, three (one case from the
Canadian BCFR and two controls from the Australian
BCFR) were excluded because their PCR failure rate for
MRN mutation-screening amplicons was greater than
20%. The distributions of the remaining 1,312 cases and
1,121 controls by age, race or ethnicity, and study center
are detailed in Table 1.screening quality control criterion; BCFR, Breast Cancer Family Registry.Relationship between frequency and odds ratio for
homologous recombination repair pathway breast cancer
susceptibility genes
In our case-control mutation screening studies of ATM,
CHEK2, RAD51, and XRCC2, we excluded from statis-
tical analysis sequence variants with allele frequencies
above an arbitrarily selected frequency of 0.5%. With the
availability of 1000G and EVS mutation screening data,
it is now possible to use external data to bin rare sequence
variants into allele frequency categories and then, using
independent observational data, estimate odds ratio as
a function of frequency. Results of such an analysis of
sequence variants from confirmed breast cancer sus-
ceptibility genes, for example, ATM, BRCA1, BRCA2,
and CHEK2 are summarized in Table 2 and provide
the basis for an empirically determined allele frequency
threshold.
In the 0.32% to 0.10% allele frequency bin, there was
significant evidence of pathogenic variants in CHEK2; in-
deed, the known pathogenic CHEK2 variants c.1100delC
(Chr22:29091856delG) and p.Ile157Thr (rs17879961) both
have allele frequencies between 0.32% and 0.10% in the
EVS ‘Caucasian American’ sample. But there was no evi-
dence for pathogenic variants in the other three genes in
this allele frequency range.In the 0.10 to 0.032% bin, BRCA2 had an OR of 1.60
(P = 0.078). Although just shy of significant, an elevated
BRCA2 OR in this EVS frequency bin is supported by
the presence of known pathogenic BRCA2 variants with
multiple reports in the Breast Information Core (BIC)
database such as c.2806_2809delAAAC (rs80359351) and
c.3847_3848delGT (rs80359405) [41]. While the OR for
ATM in this frequency bin was very near 1.0, our data set
did contain one known pathogenic in-frame deletion in
the gene, p.RIS2547_2549del (c.7638_7646del9), which
was observed in a control.
Below an allele frequency of 0.032%, all four genes
had significant evidence of pathogenic variants. We note
that, in genotype-phenotype terms, the MRN genes more
closely resemble BRCA1, BRCA2, and ATM than CHEK2
in that inheritance of biallelic mutations in the MRN
genes is either embryonic lethal or causes a developmental
phenotype that severely reduces reproductive fitness; we
know of no such evidence for biallelic CHEK2 mutation
carriers [42-44]. Therefore, noting that there was no evi-
dence for pathogenic variants in ATM, BRCA1, or BRCA2
with allele frequencies >0.1% in continental level popula-
tions, we set our threshold for evaluating rare MRN vari-
ants at an allele frequency ≤0.1% in Caucasian Americans,
African Americans, and East Asians, based on EVS data
Table 2 Frequency vs odds ratio for confirmed HRR breast cancer susceptibility genes









ATM¥ 0.00¢ 0.57 (0.12-2.80) 1.13 (0.30-4.24) 2.61 (1.57-4.35)
BRCA1§ no variants no variants no variants 2.06 (1.06-4.57)
BRCA2§ no variants 0.96 (0.64-1.43) 1.60 (0.95-2.70) 1.57 (1.15-2.15)
CHEK2† 0.99 (0.20-4.91) 3.40 (1.22-9.47) 1.68 (0.29-9.78) 3.31 (1.49-7.37)
Boldface within the table indicates P <0.05. ¥Underlying data from [19]. Analyses were performed on data from the nine bona fide case-control studies. Missense
substitutions were only included if they fell after position 1960 in the protein sequence. Odds ratios adjusted for study, ethnicity and mutation-screening method
employed. ¢This grouping included just one missense substitution carried by just one control subject. §Underlying data from [33]. †Underlying data from [20];
odds ratios adjusted for study center and race/ethnicity.
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rized by the NGRL Manchester, for East Asian allele
frequencies [40].
Analyses of rare silent substitutions and rare, analytically
innocuous splice junction variants
Full open reading frame mutation screening of the MRN
genes revealed 20 rare silent substitutions and 21 splice
junction variants that look innocuous by the MaxEntScan
based sequence analysis criteria described in the Methods
(Table S1 in Additional file 1). Accounting for subjects who
carried two rare variants, 10 cases and 10 controls carried a
rare silent substitution and no other potentially more severe
rare variant, resulting in an OR of 0.95 (P = 0.91). Similarly,
14 cases and 13 controls carried an innocuous rare splice
junction variant and no other potentially more severe rare
variant, resulting in an OR of 0.62 (P = 0.25) (Table 3).
Analysis of protein-truncating variants
Full open reading frame mutation screening of the MRN
genes revealed three nonsense substitutions, five frameshift
variants, one severely damaging splice donor variant, one
severely damaging splice acceptor variant, and two moder-
ately damaging splice donor variants (Table 4 and Table S1
in Additional file 1). Of these 12 variants, only one, RAD50
c.2938del5, was carried by more than one subject (two con-
trols). In addition, one of these 12 variants, RAD50
c.3852del4, falls in a final coding exon where it would notTable 3 Analyses of largely innocuous groups of rare variants




Any rMS or in-frame indel¥ 48 38
†In these binary logistic regressions, the regression coefficient = ln(OR). ¥Includes th
in-frame deletion because it should not cause nonsense-mediated decay. One subje
substitution. For analyses summarized in this table, this subject was categorized as
three controls) carried both a rare missense substitution and a rare silent substitutio
carriers of a rare missense substitution. One subject (a case) carried both a rare mis
summarized in this table, this subject was categorized as a carrier of a rare missens
missense substitutions. In this table, these subjects were categorized as carriers of atrigger nonsense-mediated decay. Analytically, we consi-
dered this as being analogous to an in-frame deletion and
included the variant in our analyses of rMS and in-frame
deletions rather than our analysis of T + SJV. With nine
T + SJV observations in cases against three in controls,
the OR for T + SJV was 2.61, P = 0.14 (Table 5).
Analyses of rare missense substitutions and in-frame
indels
We observed 58 distinct rMS, one in-frame deletion,
and one final exon frameshift (RAD50 c.3852del4) that we
treated as an in-frame deletion (Table S1 in Additional
file 1). Taking into account that two subjects (one case
and one control) carried two rMS, these added up to 48
cases and 38 controls that carried one or more rMS or
in-frame indel. The OR for this class of variants was
0.96 (P = 0.85) (Table 3).
In our analyses of BRCA1 and BRCA2, we found that
evidence for pathogenic, non-spliceogenic, missense sub-
stitutions in those genes was limited to substitutions that
fall in the protein’s key functional domains and have
severity scores of greater than C0 when evaluated by
Align-GVGD [33,38]; that observation is also supported
by an extensive functional assay analysis of BRCA1 mis-
sense substitutions [45]. In our case-control mutation
screening analysis of ATM, we also found that evidence
for rMS that predispose to breast cancer was limited to
rMS with Align-GVGD severity scores of greater thann Crude OR (95% CI) Adjusted OR† (95% CI)
0.85 (0.35-2.06) 0.95 (0.38-2.39)
0.92 (0.43-1.96) 0.62 (0.28-1.39)
1.08 (0.70-1.67) 0.96 (0.61-1.50)
e carrier of the RAD50 final exon frameshift c.3852del4, which we treat as an
ct (a case) carried both a rare innocuous splice donor variant and a rare silent
a carrier of an innocuous splice junction variant. Four subjects (one case and
n. For analyses summarized in this table, these subjects were categorized as
sense substitution and a rare innocuous splice acceptor variant. For analyses
e substitution. Two subjects (one case and one control) carried two rare
rare missense substitution. OR, odds ratio; CI, confidence interval.
Table 4 Severity scores applied to selected classes of potentially pathogenic rare variants
Class Binary Graded #Variants Cases, n Controls, n
severity severity
Truncating and spliceogenic variants
Frameshift, excluding the last exon 1.0 6.0 4 2 3
Nonsense, excluding the last exon 1.0 6.0 3 3 0
Severe acceptor damage 1.0 5.7 1 1 0
Moderate acceptor damage 1.0 2.4 0 0 0
Severe donor damage 1.0 5.7 1 1 0
Moderate donor damage 1.0 2.4 2 2 0
Missense
Key domain rMS, graded C0 0.0 0.0 4 4 1
Key domain rMS, graded C15 1.0 1.0 1 1 0
Key domain rMS, graded C25 1.0 2.0 6 6 1
Key domain rMS, graded C35 1.0 3.0 1 0 1
Key domain rMS, graded C45 1.0 4.0 3 3 0
Key domain rMS, graded C55 1.0 5.0 0 0 0
Key domain rMS, graded C65 1.0 6.0 8 10 1
Key domain in-frame deletion† 1.0 6.0 1 0 1
†Includes the RAD50 final exon truncating variant c.3852del4, which falls within the C-terminal ATPase domain (a key domain), which we consider analytically
equivalent to a key domain rMS graded C65. rMS, rare missense substitution.
Damiola et al. Breast Cancer Research 2014, 16:R58 Page 7 of 16
http://breast-cancer-research.com/content/16/3/R58C0 that fall in the key functional domains of the protein
that are central to its enzymatic activity [19]. Accor-
dingly, we carried out an analysis of MRN gene rMS
limited to these key functional domains, largely as de-
scribed in a recent review of MRN protein structure and
function [4] with the exception that we excluded from
the analysis variants falling in the second DNA binding
domain of MRE11A because this domain is required for
DSB formation during meiosis but not for repair of
DSBs [46].
Limited to the key functional domains as annotated on
Figure 1 (which is derived from Williams et al. [4]), and
excluding the second DNA binding domain of MRE11A,
we observed 23 rMS and one final exon truncating vari-
ant that we evaluate as an in-frame deletion (RAD50
c.3852del4). These variants were carried by 24 cases
and five controls, resulting in an OR of 3.17 (P = 0.012)
(Table 5 and Table S1 in Additional file 1).
To refine analyses of the key domain rMS, we pre-
pared and hand-curated protein multiple sequence align-
ments of the MRN proteins. Each alignment contains 16
sequences from MRN orthologs and, from the perspec-
tive of the position of Homo sapiens in the vertebrate
phylogeny, each samples the same key nodes of mamma-
lian and vertebrate evolution. The concatenated align-
ment slightly exceeds an average of 3.0 substitutions per
position, reaching our criterion of sufficient sequence di-
versity for evaluating missense substitutions [36]. Using
these alignments, the key domain rMS were scored withAlign-GVGD and SIFT; PolyPhen-2 scores for these var-
iants were also extracted from PolyPhen’s pre-computed
exome-wide data set [32,64,65]. The key domain final
exon truncating variant RAD50 c.3852del4 was assigned
Align-GVGD, SIFT, and PolyPhen-2 scores correspond-
ing to the most severe missense substitution created by
the frameshifted coding; these were C65, 0.00, and 0.996,
respectively (Align-GVGD and PolyPhen-2 scales have
the opposite polarity of the SIFT scale; all three of these
scores are indicative of an extremely damaging variant).
Accordingly, for all further analyses described here,
RAD50 c.3852del4 is included in the most severe grade
of key domain rMS unless otherwise noted.
A conservative view of protein multiple sequence
alignment-based evaluation of human missense substitu-
tions is that each missense substitution that falls within
or very close to the range of variation observed at its po-
sition in an appropriately informative alignment should
be neutral or nearly so. With Align-GVGD, this would
correspond to missense substitutions that score C0.
Using the complete alignments of the MRN proteins, 11
of the key domain rMS scored C0; these were carried by
11 cases and just one control, potentially indicative of
overly stringent alignment depth. Reducing the strin-
gency of the Align-GVGD scoring by restricting the
alignments to the mammals-only subset (comprising se-
quences from nine species), four of the key domain rMS
scored C0, and these were carried by four cases and









DNA binding #1 (294-461) 
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Figure 1 MRE11, RAD50, and nibrin key functional domains. The protein domain diagrams are updated from Williams et al. [4] and include
information from the InterPro protein sequence analysis and classification database, the Uniprot Protein Knowledgebase, and the NCBI Conserved
Domains Database [47-50] plus structural studies of the MRN proteins [51-63].
Table 5 Analyses of potentially pathogenic groups of rare variants






Total 9 3 2.60 (0.70-9.65) 2.61 (0.67-10.1)




Total 24 5 4.18 (1.59-11.0) 3.17 (1.17-8.59)




Total 20 4 4.34 (1.48-12.7) 3.07 (1.01-9.31)




Total 29 7 3.60 (1.57-8.24) 2.88 (1.22-6.78)
Boldface within the table indicates P <0.05. †In these binary logistic regressions, the regression coefficient = ln(OR). ¥Truncating and splice junction variants;
excludes final exon nonsense and frameshift variants. $One subject (a case) carried both the RAD50 splice acceptor variant RAD50_c.552-1G > A and the RAD50
silent substitution RAD50 c.3153G > A (p.L1051L). *The key functional domains are defined in Figure 1. The set of variants includes rare missense substitutions with
A-GVGD scores > C0, and final exon nonsense and frameshift variants if they also fall in a key functional domain. ¢One subject (a case) carried both the MRE11A
key domain rare missense substitution MRE11A p.D235G and the NBN non key domain rare missense substitution NBN p.V210F. OR, odds ratio; CI, confidence
interval.
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ried by 20 cases and four controls (Table 5 and Table S1
in Additional file 1). The OR for the non-C0 key domain
rMS and in-frame deletions was 3.07 (P = 0.029).
Exploiting the intrinsic ordering of the seven Align-
GVGD grades from C0 to C65, we performed a logistic
regression test for log-linear OR trends across noncar-
riers and carriers of the seven grades of rMS. In this test,
the C0 substitutions are again considered very likely
neutral and assigned a severity grade of 0, which was the
same as the grade assigned to noncarriers. The more se-
vere grades were assigned sequentially higher severities,
with C65 substitutions assigned a severity grade of 6
(Tables 4 and 6). The test yielded a lognormal OR in-
crease of 0.21/grade (P = 0.077), which corresponds to a
modeled OR of 3.60 at grade 6 (Table 6).
Truncating variants and rare missense substitutions
assessed in a single model
Using a simple binary classification to combine T + SJV
plus key functional domain rMS of grade > C0 into a
single model, we observed 29 carriers among the cases
against seven among the controls. This binary classifica-
tion resulted in an OR of 2.88, P = 0.0090 (Table 5).
To add the T + SJV into the regression test for OR trend
across the graded rMS, we assigned protein-truncating
variants a severity grade equal to that of the highest grade
rMS included in that regression, in this case 6.0. Poten-
tially damaging splice junction variants were assigned this
severity grade x their probability to damage a splice junc-
tion, that is, severely damaging splice junction variants
were assigned a severity grade of 0.95 × 6 = 5.7, and mod-
erately damaging splice junction variants a severity grade
of 0.40 × 6 = 2.4. This test yielded a lognormal OR increaseTable 6 Graded tests
Class Adjusted? ln(OR) regre
coefficient*
MRN Key Domain missense, graded$ crude 0.30 (0.055-
adjusted 0.21 (−0.052-
MRN T + SJV, graded crude 0.14 (−0.088-
adjusted 0.15 (−0.091-
MRN T + SJV + KeyD missense, graded$ crude 0.23 (0.059-
adjusted 0.18 (0.0011
MRN T + SJV + KeyD missense, graded$
(C65 rMS and in-frame indel removed)
crude 0.31 (0.0094
adjusted 0.33 (0.028-
Boldface within the table indicates P <0.05. *From a standard logistic regression of
coefficient, and x is, in this case, sequence variant grade. Note that the regression c
the most severe grade included in the logistic regression, using the ln(OR) regressio
grade included in the corresponding graded regression model. $The key functional
nonsense and frameshift variants if they also fall in a key functional domain. ¢This i
C65 rMS and in-frame indels, truncating variants, and severely damaging splice junc
C55 rMS in the data set (Table 4), this is a four-grade regression with the most seve
damaging splice junction variants. OR, odds ratio; CI, confidence interval.of 0.18/grade (P = 0.033), which corresponds to a modeled
OR of 2.89 at the most severe grade (Table 6).
In addition to the lognormal OR coefficient and mo-
deled OR at the most severe sequence variant grade,
Table 6 also reports the OR point estimate at the most
severe sequence variant grade. One unusual result was
that, for the analysis or rMS, the logistic regression ad-
justment for race/ethnicity and study center decreased
the modeled OR for key domain C65 rMS by 42% and
decreased the OR point estimated for this class of rMS
by 58% compared to the crude result. These ORs also
decreased in the combined test of rMS plus T + SJV, but
not as dramatically.
Looking at the underlying data, 11 of the 12 observa-
tions of key domain C65 rMS - including both controls
that carried such a variant - were carried by either an
East Asian or a Latina. Because the case:control ratio in
these groups was 3:1 (Table 1), the adjustment for race/
ethnicity applies a relatively high weight to the geno-
types of the East Asian and Latina controls, explaining
the marked decrease in the OR point estimates upon ad-
justment. As clustering of C65 rMS in the East Asian
and Latina subjects was an unexpected heterogeneity in
our data set, we checked for heterogeneity across racial/
ethnic groups by class of likely pathogenic sequence
variant (Table 7). While there was no evidence for het-
erogeneity in the distributions of T + SJV or rMS in ge-
neral, subset analysis found racial/ethnic heterogeneity
across the key domain rMS (P = 0.003) and sub-subset
analysis found that this heterogeneity was localized ex-
clusively to the key domain C65 variants (P = 0.96 for
rMS of grade C0 to C55, but P <1x10−5 for C65 rMS).
To examine the impact of racial/ethnic heterogeneity in
the distribution of key domain C65 rMS on the evidencession
(95% CI)
Modeled OR at most
severe grade† (95% CI)
Observed OR at most
severe grade¥ (95% CI)
0.55) 6.16 (1.39-27.3)¢ 4.31 (0.94-19.7)¢
0.48) 3.60 (0.73-17.7)¢ 1.80 (0.38-8.44)¢
0.37) 2.34 (0.59-9.34)¢ 2.03 (0.52-7.86)¢
0.38) 2.41 (0.58-10.0)¢ 2.15 (0.53-8.78)¢
0.39) 3.90 (1.42-10.7)¢ 2.93 (1.08-7.97)¢
-0.35) 2.89 (1.01-8.30)¢ 1.97 (0.69-5.62)¢
-0.62) 3.50 (1.04-11.8)∞ 2.88 (0.79-10.5)∞
0.64) 3.79 (1.12-12.9)∞ 3.43 (0.91-12.9)∞
form ln(OR) = a + b(x) in which a = 0, b is the logistic regression OR trend
oefficient is significant if its 95% CI excludes 0.00. †This is the OR calculated for
n coefficient. ¥This is the OR point estimate for carriers of the most severe
domains are defined in Figure 1. The set of variants includes final exon
s a six-grade regression with the most severe grade consisting of key domain
tion variants. ∞With C65 rMS and the in-frame indel removed, and with no
re grade consisting of key domain C45 rMS, truncating variants, and severely




Heterogeneity across racial/ethnic groups
by sequence variant class
Racial/ethnic group: T + SJV 0.11 NA¥
Racial/ethnic group: any rMS 0.35 NA¥
subset: non-key domain rMS*: 0.40 NA¥
subset: key domain rMS*: 0.003 NA¥
sub-subset: key domain rMS*, <C65 0.96 NA¥
sub-subset: key domain rMS*, C65 <1x10−5 NA¥
Heterogeneity across genes, by likely
pathogenic sequence variant class
MRN: T + SJV 0.43 NC†
MRN: key domain rMS* 1.00 0.68
MRN: rare T + SJV and key domain rMS* 0.53 0.30
¥We have adjusted most P values for racial/ethnic group and study center. But
a test for heterogeneity across racial ethnic groups cannot be adjusted for
racial/ethnic group; moreover, as most of the subjects of East Asian, Latina,
and Recent African Ancestry were obtained from one study center (the Cancer
Prevention Institute of California), we cannot adjust these tests on that
variable, either. †Adjusted P value could not be calculated because some cells
contained 0. *The key functional domains are defined in Figure 1. The set of
variants includes rare missense substitutions with A-GVGD scores > C0, and
final exon nonsense and frameshift variants if they also fall in a key functional
domain. T + SJV, truncating and splice junction variants; rMS, rare missense
substitution; MRN, MRE11-RAD50-NBN complex.
Table 8 Impact of race/ethnicity heterogeneity in
distribution of rare key domain C65 missense
substitutions









Total 10 2 4.35 (0.95-19.9) 1.78 (0.38-8.35)




Total 10 2 4.34 (0.95-19.9) 4.55 (0.97-21.3)




Total 19 5 3.30 (1.23-8.87) 3.39 (1.23-9.33)





Total 14 4 4.04 (1.33-12.3) 4.08 (1.32-12.5)
Boldface within the table indicates P <0.05. †In these binary logistic
regressions, the regression coefficient = ln(OR). *The key functional domains
are defined in Figure 1. §Eight distinct key functional domain C65 missense
substitutions and the RAD50 final exon frameshift c.3852del4 fall in this group
(Table 4). $Eleven distinct key functional domain missense substitutions fall in
this group (Table 4). ¥Truncating and splice junction variants; excludes final
exon nonsense and frameshift variants. ¶Limiting to CEU (Caucasians of
European ancestry) subjects reduces the number of case and control
noncarriers to 834 and 963, respectively. rMS, rare missense substitution;
T + SJV, truncating and splice junction variants.
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cancer susceptibility genes, we assessed the key domain
C65 missense substitutions alone and re-ran the binary
analysis of T + SJV and key domain rMS with the C65
variants excluded (Table 8). The crude OR for key domain
C65 missense substitutions alone was 4.3, but dropped to
1.78 upon adjustment for race/ethnicity and study center.
Nonetheless, excluding these C65 rMS from the binary
analysis of T + SJV and key domain rMS resulted in an OR
of 3.39 (Table 5), and the P value (P = 0.010) was virtually
identical to that observed when the C65 rMS were in-
cluded (P = 0.0090). Similarly, setting aside the issue of ra-
cial/ethnic heterogeneity by limiting the binary analysis of
T + SJVs and key domain rMS to Caucasians of European
ancestry resulted in an OR of 4.08 (P = 0.0068) (Table 8).
Finally, exclusion of the key domain C65 rMS from the
graded test of rMS and T + SJV resulted in a lognormal
OR increase of 0.33/grade (P = 0.021) and virtually no
change in the OR coefficient upon adjustment (Table 6).
Thus the racial/ethnic heterogeneity in the distribu-
tion of these rMS does not impinge on the overall
result of this study. Of note, among the key domain C65
rMS, the RAD50 zinc hook domain missense substitu-
tion p.Arg725Trp was observed in three Latina cases;
the EVS reports that the variant was observed in 1 of
2,200 African Americans and the variant was not present
in 1000G data.Discussion
In the present work, we evaluated the contribution of
rare variants in the genes MRE11A, RAD50, and NBN to
breast cancer risk. As the proteins encoded by these
genes form an evolutionarily conserved complex that
could be functionally impaired by a dysfunctional variant
in any one of the genes, we evaluated them as if they
constitute a single candidate susceptibility gene. Com-
bining T + SJV, and key functional domain rMS, we found
that this set of rare MRN genes variants contributes to
breast cancer susceptibility (OR = 2.88, P = 0.0090). A post
hoc test for heterogeneity did not reveal evidence for
between-gene differences in the case-control distributions
of likely pathogenic variants: Fisher’s exact test P values of
between-gene heterogeneity for T + SJV, key domain rMS
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were 0.43, 1.00, and 0.53, respectively (Table 7). Similarly,
looking at the genes individually, neither truncating vari-
ants, nor key domain missense substitutions, nor a com-
bination of the two reached statistical significance from
single gene data (Table 9). Thus evidence from this study
in favor of the MRN genes as intermediate-risk breast can-
cer susceptibility genes emerges from the ensemble ana-
lysis of the three genes.
Although MRN gene T + SJV were not by themselves a
significant breast cancer risk factor, we note that our OR
point estimate of 2.61 is both very close to the meta-
analysis point estimate of 2.63 that Zhang et al. obtained
for NBN c.657del5 [13], and close to the point estimate
of 2.32 that we obtained in our meta-analysis of ATM
T + SJV [19]. Thus, while we cannot exclude that our
nonsignificant finding is actually indicative of little or no
risk of breast cancer conferred by MRN gene protein-
truncating variants, our data are more strongly in accord
with the hypothesis that they confer an intermediate risk
of magnitude similar to the risk conferred by truncating
variants in ATM.
Overall, there was no association between rMS and
risk of breast cancer. Nevertheless, tightening the focusTable 9 Individual contributions of MRE11A, RAD50, and NBN
Class Cases, n Controls, n
Noncarriers 1,283 1,114
MRE11A
T + SJV¥ 1 0
rMS or IFD*¢ 7 1
Combined 8 1
RAD50
T + SJV¥$ 4 3
rMS or IFD* 10 2
Combined 14 5
NBN
T + SJV¥ 4 0
rMS or IFD* 3 1
Combined 7 1
MRE11A, RAD50, and NBN ensemble model*
T + SJV¥$ 9 3
rMS or IFD*¢ 20 4
Combined 29 7
Boldface within the table indicates P <0.05. †In these binary logistic regressions, th
excludes final exon nonsense and frameshift variants. ¥Because there were no obse
(∞) and the P value was calculated by Fisher exact test rather than by logistic regre
confidence intervals could not be estimated, we report the P value. *Key functional
and final exon nonsense and frameshift variants if they also fall in a key functional
case) carried both the MRE11A key domain rare missense substitution MRE11A p.D2
$One subject (a case) carried both the RAD50 splice acceptor variant RAD50 c.552-1
truncating and splice junction variants; rMS, rare missense substitution; IFD, in-framto key functional domain rMS resulted in a significant
association with an OR of approximately 3.0. In this
sense, the MRN genes behave as the homologous recom-
bination repair genes BRCA1, BRCA2, and ATM - genes
in which rare missense substitutions that are pathogenic
because of missense dysfunction per se are largely con-
fined to key functional domains.
Combining MRN T + SJV and key functional do-
main rMS, we observed an OR of 2.88 with a P value of
0.0090. That P value meets the threshold of P <0.01 that
Hollestelle et al. suggested for establishing intermediate-
risk susceptibility genes that were already strong candi-
dates based on their biochemical function [3]. Thus with a
mutation screening and data analysis approach that con-
sidered MRE11A, RAD50, and Nibrin as a unique func-
tional entity and focused the analysis of rMS to those that
fall in the key functional domains of the MRN complex,
we overcame the limitation of previous suggestive studies
that were based on a small number of founder mutations
[13,15,18], and confirmed the hypothesis that MRE11A,
RAD50, and NBN are intermediate-risk susceptibility
genes in a general sense. Moreover, because we did not
observe any of the four sequence variants most respon-
sible for the MRN genes’ candidate gene status (MRE11Ato the ensemble model
Crude OR† (95% CI) Adjusted OR† (95% CI)
∞[P = 1.00]¥
6.08 (0.75-49.5) 3.62 (0.42-31.5)
6.95 (0.87-55.6) 5.02 (0.59-42.8)
1.16 (0.26-5.18) 1.09 (0.23-5.24)
4.34 (0.95-19.9) 3.21 (0.68-15.2)
2.43 (0.87-6.77) 1.98 (0.68-5.71)
∞[P = 0.13]¥
2.60 (0.27-25.1) 2.12 (0.20-22.6)
6.08 (0.75-49.5) 5.28 (0.62-45.2)
2.60 (0.70-9.65) 2.61 (0.67-10.1)
4.34 (1.48-12.7) 3.07 (1.01-9.31)
3.60 (1.57-8.24) 2.88 (1.22-6.78)
e regression coefficient = ln(OR). ¥Truncating and splice junction variants;
rvations of this class of variants in the controls, the crude odds ratio is infinity
ssion; this also precludes calculation of adjusted odds ratios. As 95%
domain rare missense substitutions with A-GVGD scores > C0, in-frame indels,
domain. The key functional domains are defined in Figure 1. ¢One subject (a
35G and the NBN non key domain rare missense substitution NBN p.V210F.
G > A and the RAD50 silent substitution RAD50 c.3153G > A (p.L1051L). T + SJV,
e deletion.
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and NBN c.657del5) [13,14,18], this confirmation is inde-
pendent of the hypothesis-generating data.
Five of the sequence variants observed in the MRN
case-control mutation screening bear further discussion.
NBN p.Arg215Trp was of interest because association
studies have found evidence that it confers modest risk
of several cancers (for review, see [66]), and there is bio-
chemical evidence, albeit somewhat conflicting, of al-
tered function of this nibrin allele [67,68]. We observed
six cases and six controls with the p.Arg215Trp missense
substitution, resulting in an OR of 0.96 (95% CI 0.30 to
3.06, P = 0.95). While these confidence intervals are too
wide to exclude the possibility that NBN p.Arg215Trp is
actually a modest-risk variant, we also point out that
position Arg215 is quite variable in our protein multiple
sequence alignment and that, according to EVS data, the
variant has a frequency of 0.37% in Caucasian Americans -
well above the frequency threshold we found for severely
dysfunctional variants in homologous recombination re-
pair genes in which biallelic mutations cause embryonic
lethality or severe childhood disease.
Second, we observed one carrier, a Caucasian control
ascertained at the age of 55, of the MRE11A in-frame
deletion c.2109del9. The variant falls in the last exon of
the gene, near the carboxy terminus of the second DNA
binding domain (which is also the carboxy terminus of
the protein). Because this domain is required for double-
strand break formation during meiosis but not for repair
of double-strand breaks [46], the domain was not in-
cluded in the list of ‘key functional domains’ and the
indel was not included in statistical analyses of key func-
tional domain variants.
Third, we observed one carrier, an East Asian case di-
agnosed at the age of 35, of MRE11A p.Thr481Ile. This
residue is a threonine in all but one species in our align-
ment, but is a methionine in the cephalochordate, Bran-
chiostoma lanceolatum. The substitution falls within the
protein’s RAD50 interaction domain. While very few of
the rare variants that we observed have been reported in
human ataxia-telangiectasia-like disease or Nijmegen
breakage syndrome patients, another substitution at this
residue, p.Thr481Lys, was observed in an Italian ataxia-
telangiectasia-like disease sib-pair [69].
Fourth, we observed one carrier, an East Asian control
ascertained at age 50, of the RAD50 frameshift c.3852del4.
Because the frameshift falls in the last exon of the gene
where it would not be expected to cause nonsense-
mediated decay of the mRNA, we evaluated it as an
in-frame deletion rather than as a frameshift. As such,
it scrambles well-conserved sequence near the carboxy
terminus of the protein’s carboxy-end ATPase domain and
final MRE11A binding domain including positions such as
Arg1288 and Lys1291 that are invariant in our proteinmultiple sequence alignment. The sequence scrambling
creates nonconservative substitutions at invariant key
functional domain positions, resulting in the highest pos-
sible sequence variant severity score.
Fifth, we observed one carrier, also an East Asian con-
trol ascertained at age 50, of the NBN missense substi-
tution p.Ile35Thr. This position falls in the protein’s
functionally important forkhead-associated (FHA) domain
and is either isoleucine or leucine in all of the species in-
cluded in our NBN protein multiple sequence alignment.
The last three variants described above illustrate two
of the analytic problems encountered in this study. All
three were evaluated as key domain C65 rMS and all
three were observed in East Asian subjects. Combined
with eight additional observations of key domain C65
rMS in either East Asian or Latina subjects against just
one in a Caucasian of European ancestry, there was an un-
expected excess of these variants in the non-Caucasian
subjects mutation screened in this study. Second, the two
variants observed in the controls affected positions with
little or no cross-species physicochemical variability; con-
sequently, they would be graded as severe C65 variants
with either a mammals-only protein multiple sequence
alignment or with our complete alignment through the
deuterostomate Strongylocentrotus purpuratus. In con-
trast, the MRE11A rMS that described from a breast can-
cer case (p.Thr481Ile), as well as the rMS observed at the
same position in a pair of ataxia-telangiectasia-like disease
cases (p.Thr481Lys), score as severe C65 substitutions
when evaluated with the mammals-only alignment but as
likely innocuous C0 substitutions when evaluated with the
evolutionarily deep alignment. Since the observation of a
nonconservative rMS at MRE11A position Thr481 in a
pair of ataxia-telangiectasia-like disease cases increases
the odds that substitutions at this position are in fact
pathogenic, it appears that using the evolutionarily deeper
alignments is, for the MRN genes, counterproductive.
On the other hand, the empirically determined allele
frequency thresholds derived by combining older ATM,
BRCA1, BRCA2, and CHEK2 case-control mutation scree-
ning data with EVS and 1000G data - found to be 0.1% for
the three genes (ATM, BRCA1, and BRCA2) where inhe-
ritance of biallelic mutations is either embryonic lethal or
causes a developmental phenotype that severely reduces
reproductive fitness, and 0.32% for CHEK2 - provides a
new tool to help with evaluation of the many rare variants
observed in a case-control mutation screening study of
candidate cancer susceptibility genes.
For BRCA1 and BRCA2, it is well established that a
strong majority of pathogenic variants are, ultimately,
protein-truncating variants. In contrast, case-control mu-
tation screening of CHEK2 revealed an approximately
equal contribution from T + SJVs and rMSs to the fraction
of breast cancer attributable to rare variants in that gene,
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of ATM revealed that rMS in that gene may actually
be responsible for a larger fraction of the breast can-
cer attributable to rare variants than are the T + SJVs
[19,20]. In the mutation screening data reported here,
rare key functional domain missense substitutions in
the MRN genes were more frequent (24 vs. 12 observa-
tions) than truncating variants and conferred a slightly
higher OR (3.07 vs. 2.61) with a lower P value (0.029 vs.
0.14). These data are more congruent with the ATM/
CHEK2 pattern than the BRCA1/2 pattern. Since there is
not yet any efficient approach to clinically actionable clas-
sification of missense substitutions in these genes, these
data point toward a clinical problem. When the MRN
genes are mutation screened as part of a clinical panel-
based cancer susceptibility gene sequencing test, a large
fraction, if not the majority, of the genetic risk attributable
to them will reside in rare missense substitutions that will
initially be reported to clinical geneticists as unclassified
variants.
The analytic strategy of treating the three genes as a
single concatenated gene had one notable drawback: we
are not able to ask whether variants in each of the three
genes are best evaluated under the same analysis model.
Thus an enormous amount of work, likely involving larger
scale mutation screening efforts to gain more analytic pre-
cision, tests of segregation to examine penetrance and
tumor spectrum, and perhaps development of functional
assays to aid evaluation of rare missense substitutions, re-
mains to be performed on with MRE11A, RAD50, and
NBN.Conclusions
Results reported here establish that MRE11A, RAD50,
and NBN are intermediate-risk breast cancer susceptibil-
ity genes and help to justify their inclusion on panel-
based cancer susceptibility gene tests. Protein-truncating
variants and rare missense substitutions falling in the
key functional domains of these proteins appear to con-
fer two- to three-fold increased risk of breast cancer.
Like ATM and CHEK2, the spectrum of pathogenic var-
iants in the MRN genes includes a relatively high pro-
portion of missense substitutions. However, the data
neither establish whether variants in each of the three
genes are best evaluated under the same analysis model
nor achieve clinically actionable classification of individ-
ual variants observed in this study. Given the relatively
low frequency of likely pathogenic variants in the MRN
genes, development of clinically applicable rare mis-
sense substitution classification models for these genes
will require data from very large observational studies sup-
plemented, in all likelihood, by carefully calibrated func-
tional assays.Additional file
Additional file 1: Table S1. This spreadsheet contains anonymized
coded observational data sufficient to perform most of the analyses
of the MRN case-control mutation screening data described in this
manuscript.
Abbreviations
1000G: 1000 genomes project; Align-GVGD: Align Grantham variation
Grantham deviation; ATM: ataxia telangiectasia mutated; BCFR: Breast Cancer
Family Registry; BIC: Breast Cancer Information Core; bp: base pair;
BRCA1: Breast Cancer 1 gene; BRCA1/2: BRCA1 and/or BRCA2; BRCA2: Breast
Cancer 2 gene; CHEK2: checkpoint kinase 2; CI: confidence interval; CIHR:
Canadian Institutes for Health Research; DSB: double-strand breaks;
EVS: exome variant server; HRM: high-resolution melting curve analysis;
IARC: International Agency for Research on Cancer; IRB: Institutional Review
Board; MES: MaxEntScan; MIM: Mendelian Inheritance in Man; MRE11A:
meiotic recombination 11; MRN complex: MRE11-RAD50-NBN complex;
NBN: nibrin; NCI: United States National Cancer Institute; NGRL Manchester:
UK National Reference Laboratory Manchester; NIH: United States National
Institutes of Health; OR: odds ratio; PCR: polymerase chain reaction;
PHYLIP: Phylogeny Inference Package; PolyPhen: polymorphism phenotyper;
rMS: rare missense substitution; SIFT: Sorting Intolerant from Tolerant;
SNP: single-nucleotide polymorphism; T- or M-Coffee: Tree-based consistency
objective function for alignment evaluation; T + SJV: truncating and splice
junction variants; WGA DNA: whole-genome amplified deoxyribonucleic acid;
XRCC2: X-ray cross complemention group 2.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
FD led the mutation screening of RAD50, contributed to data analysis, and
helped to draft the manuscript. MP led the mutation screening of NBN,
contributed to data analysis, and helped to draft the manuscript. JO led the
mutation screening of MRE11A, contributed to data analysis, and helped to
draft the manuscript. FLCK contributed to study design, led the laboratory
team, and helped to draft the manuscript. CV was responsible for data
management throughput for the project, helped to refine the laboratory
platform, and helped to draft the manuscript. ELY built and curated the MRN
protein multiple sequence alignments, helped with scoring missense
substitutions, and helped to draft the manuscript. NR contributed to the
mutation screening and data analysis, helped to refine the laboratory
platform, and helped to draft the manuscript. NF contributed to the
mutation screening and data analysis, helped to refine the laboratory
platform, and helped to draft the manuscript. GD contributed to the
mutation screening and data analysis, helped to refine the laboratory
platform, and helped to draft the manuscript. MPV built the algorithm
for evaluating splice junction variants and helped to draft the
manuscript. KT contributed to evaluation of splice junction variants and
helped to draft the manuscript. TCR adapted the splice junction analysis
algorithm to run on sequence variants written in genome coordinates
and helped to draft the manuscript. GJW defined the coordinates of
the MRN protein key functional domains and helped to draft the
manuscript. JLH was the lead investigator for subjects gathered through
the Australian site of the BCFR and helped to draft the manuscript.
MCS contributed to study design, contributed to the management of
samples obtained through the Australian site of the BCFR, and helped
to draft the manuscript. ILA was the lead investigator for subjects
gathered through the Ontario site of the BCFR and helped to draft the
manuscript. EMJ was the lead investigator for subjects gathered through
the Northern California site of the BCFR and helped to draft the
manuscript. DEG contributed to study design, contributed to the analysis
of rare variants in BRCA1 and BRCA2, gave advice on analysis of the
MRN data, and helped to draft the manuscript. FL contributed to study
design and data analysis, and helped to draft the manuscript. SVT was
responsible for overall study design, contributed to data analysis, and
helped to draft the manuscript. All authors read and approved the
final manuscript.
Damiola et al. Breast Cancer Research 2014, 16:R58 Page 14 of 16
http://breast-cancer-research.com/content/16/3/R58Acknowledgements
We wish to thank all participants in the BCFR for their contribution to the
study. We also appreciate the support of J. McKay and the Genetic Cancer
Susceptibility group at IARC.
Funding statement
This work was supported by the United States National Institutes of Health
(NIH) National Cancer Institute (NCI) grant R01 CA121245, by the Canadian
Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of
Breast Cancer program, by the Government of Canada through Genome
Canada and the Canadian Institutes of Health Research, and the Ministère de
l’enseignement supérieur, de la recherche, de la science, et de la technologie
du Québec through Génome Québec. The BCFR was supported by grant
UM1 CA164920 from the NCI. The work also benefited from the Huntsman
Cancer Institute’s Bioinformatics Shared Resource, which is supported by NCI
grant P30 CA042014. The content of this manuscript does not necessarily
reflect the views or policies of the NCI or any of the collaborating centers in
the BCFR, nor does mention of trade names, commercial products, or
organizations imply endorsement by the U.S. Government or the BCFR.
Author details
1Genetic Cancer Susceptibility group, International Agency for Research on
Cancer, 150 cours Albert Thomas, Lyon 69372, France. 2Genetic of Breast
Cancer group, Cancer Research Center of Lyon, Centre Léon Bérard, 28 rue
Laennec, Lyon 69008, France. 3Department of Oncological Sciences,
Huntsman Cancer Institute, University of Utah School of Medicine, 2000
Circle of Hope, Salt Lake City, UT 84112, USA. 4University of Texas at Austin,
Austin, TX 78712, USA. 5Life Sciences Division, Lawrence Berkeley National
Laboratory, 1 Cyclotron Road, Berkeley, CA 94720, USA. 6Centre for
Epidemiology and Biostatistics, School of Population and Global Health, The
University of Melbourne, 207 Bouverie Street, Melbourne, VIC 3010, Australia.
7Genetic Epidemiology Laboratory, The University of Melbourne, 207
Bouverie Street, Melbourne, VIC 3010, Australia. 8Lunenfeld-Tanenbaum
Research Institute, Mount Sinai Hospital, Department of Molecular Genetics,
University of Toronto, 600 University Avenue, Toronto, ON M5G 1X5, Canada.
9Cancer Prevention Institute of California, 2201 Walnut Avenue, Fremont, CA
94538, USA. 10Department of Dermatology, Huntsman Cancer Institute,
University of Utah School of Medicine, 2000 Circle of Hope, Salt Lake City, UT
84112, USA. 11Genetic Epidemiology of Cancer team, Inserm, U900, Institut
Curie, Mines ParisTech, 26 rue d’Ulm, Paris 75248, France. 12Stanford
University School of Medicine and Stanford Cancer Institute, 875 Blake Wilbur
Drive, Stanford, CA 94305, USA. 13Department of Epidemiology (Genome
Epidemiology Lab), Seoul National University School of Public Health, 599
Gwanak-ro Granak-gu, Seoul 151-742, Korea.
Received: 21 October 2013 Accepted: 8 May 2014
Published: 3 June 2014
References
1. Genetic susceptibility. In World Cancer Report 2008. Edited by Boyle P,
Levin B. Lyon: IARC Press; 2008:183–184.
2. Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M, Dennis J, Milne RL,
Schmidt MK, Chang-Claude J, Bojesen SE, Bolla MK, Wang Q, Dicks E, Lee A,
Turnbull C, Rahman N, Fletcher O, Peto J, Gibson L, Dos Santos Silva I,
Nevanlinna H, Muranen TA, Aittomaki K, Blomqvist C, Czene K, Irwanto A,
Liu J, Waisfisz Q, Meijers-Heijboer H, Adank M, van der Luijt RB, et al:
Large-scale genotyping identifies 41 new loci associated with breast
cancer risk. Nat Genet 2013, 45:353–361. 361e1-2.
3. Hollestelle A, Wasielewski M, Martens JW, Schutte M: Discovering
moderate-risk breast cancer susceptibility genes. Curr Opin Genet Dev
2010, 20:268–276.
4. Williams GJ, Lees-Miller SP, Tainer JA: Mre11-Rad50-Nbs1 conformations
and the control of sensing, signaling, and effector responses at DNA
double-strand breaks. DNA Repair (Amst) 2010, 9:1299–1306.
5. Xiao Y, Weaver DT: Conditional gene targeted deletion by Cre
recombinase demonstrates the requirement for the double-strand break
repair Mre11 protein in murine embryonic stem cells. Nucleic Acids Res
1997, 25:2985–2991.
6. Luo G, Yao MS, Bender CF, Mills M, Bladl AR, Bradley A, Petrini JH:
Disruption of mRad50 causes embryonic stem cell lethality, abnormalembryonic development, and sensitivity to ionizing radiation. Proc Natl
Acad Sci U S A 1999, 96:7376–7381.
7. Zhu J, Petersen S, Tessarollo L, Nussenzweig A: Targeted disruption of the
Nijmegen breakage syndrome gene NBS1 leads to early embryonic
lethality in mice. Curr Biol 2001, 11:105–109.
8. Waltes R, Kalb R, Gatei M, Kijas AW, Stumm M, Sobeck A, Wieland B, Varon
R, Lerenthal Y, Lavin MF, Schindler D, Dork T: Human RAD50 deficiency in
a Nijmegen breakage syndrome-like disorder. Am J Hum Genet 2009,
84:605–616.
9. Uchisaka N, Takahashi N, Sato M, Kikuchi A, Mochizuki S, Imai K, Nonoyama S,
Ohara O, Watanabe F, Mizutani S, Hanada R, Morio T: Two brothers with
ataxia-telangiectasia-like disorder with lung adenocarcinoma. J Pediatr
2009, 155:435–438.
10. Regal JA, Festerling TA, Buis JM, Ferguson DO: Disease-associated MRE11
mutants impact ATM/ATR DNA damage signaling by distinct
mechanisms. Hum Mol Genet 2013, 22:5146–5159.
11. van der Burgt I, Chrzanowska KH, Smeets D, Weemaes C: Nijmegen
breakage syndrome. J Med Genet 1996, 33:153–156.
12. Bender CF, Sikes ML, Sullivan R, Huye LE, Le Beau MM, Roth DB, Mirzoeva OK,
Oltz EM, Petrini JH: Cancer predisposition and hematopoietic failure in
Rad50(S/S) mice. Genes Dev 2002, 16:2237–2251.
13. Zhang ZH, Yang LS, Huang F, Hao JH, Su PY, Sun YH: Current
evidence on the relationship between two polymorphisms in the
NBS1 gene and breast cancer risk: a meta-analysis. Asian Pac J Cancer
Prev 2012, 13:5375–5379.
14. Heikkinen K, Karppinen SM, Soini Y, Makinen M, Winqvist R: Mutation
screening of Mre11 complex genes: indication of RAD50 involvement in
breast and ovarian cancer susceptibility. J Med Genet 2003, 40:e131.
15. Heikkinen K, Rapakko K, Karppinen SM, Erkko H, Knuutila S, Lundan T,
Mannermaa A, Borresen-Dale AL, Borg A, Barkardottir RB, Petrini J, Winqvist
R: RAD50 and NBS1 are breast cancer susceptibility genes associated
with genomic instability. Carcinogenesis 2006, 27:1593–1599.
16. Tommiska J, Seal S, Renwick A, Barfoot R, Baskcomb L, Jayatilake H, Bartkova
J, Tallila J, Kaare M, Tamminen A, Heikkila P, Evans DG, Eccles D, Aittomaki K,
Blomqvist C, Bartek J, Stratton MR, Nevanlinna H, Rahman N: Evaluation of
RAD50 in familial breast cancer predisposition. Int J Cancer 2006,
118:2911–2916.
17. Wang X, Szabo C, Qian C, Amadio PG, Thibodeau SN, Cerhan JR, Petersen
GM, Liu W, Couch FJ: Mutational analysis of thirty-two double-strand
DNA break repair genes in breast and pancreatic cancers. Cancer Res
2008, 68:971–975.
18. Bartkova J, Tommiska J, Oplustilova L, Aaltonen K, Tamminen A, Heikkinen T,
Mistrik M, Aittomaki K, Blomqvist C, Heikkila P, Lukas J, Nevanlinna H, Bartek J:
Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in
human breast cancer: MRE11 as a candidate familial cancer-predisposing
gene. Mol Oncol 2008, 2:296–316.
19. Tavtigian SV, Oefner PJ, Babikyan D, Hartmann A, Healey S, Le Calvez-Kelm F,
Lesueur F, Byrnes GB, Chuang SC, Forey N, Feuchtinger C, Gioia L, Hall J,
Hashibe M, Herte B, McKay-Chopin S, Thomas A, Vallee MP, Voegele C,
Webb PM, Whiteman DC, Sangrajrang S, Hopper JL, Southey MC, Andrulis IL,
John EM, Chenevix-Trench G: Rare, evolutionarily unlikely missense substitutions
in ATM confer increased risk of breast cancer. Am J Hum Genet 2009,
85:427–446.
20. Le Calvez-Kelm F, Lesueur F, Damiola F, Vallee M, Voegele C, Babikyan D,
Durand G, Forey N, McKay-Chopin S, Robinot N, Nguyen-Dumont T, Thomas
A, Byrnes GB, Hopper JL, Southey MC, Andrulis IL, John EM, Tavtigian SV:
Rare, evolutionarily unlikely missense substitutions in CHEK2 contribute
to breast cancer susceptibility: results from a breast cancer family
registry case-control mutation-screening study. Breast Cancer Res
2011, 13:R6.
21. Park DJ, Lesueur F, Nguyen-Dumont T, Pertesi M, Odefrey F, Hammet F,
Neuhausen SL, John EM, Andrulis IL, Terry MB, Daly M, Buys S, Le Calvez-
Kelm F, Lonie A, Pope BJ, Tsimiklis H, Voegele C, Hilbers FM, Hoogerbrugge
N, Barroso A, Osorio A, Giles GG, Devilee P, Benitez J, Hopper JL, Tavtigian
SV, Goldgar DE, Southey MC: Rare mutations in XRCC2 increase the risk of
breast cancer. Am J Hum Genet 2012, 90:734–739.
22. Le Calvez-Kelm F, Oliver J, Damiola F, Forey N, Robinot N, Durand G,
Voegele C, Vallee MP, Byrnes G, Registry BC, Hopper JL, Southey MC,
Andrulis IL, John EM, Tavtigian SV, Lesueur F: RAD51 and breast cancer
susceptibility: no evidence for rare variant association in the Breast
Cancer Family Registry Study. PLoS One 2012, 7:e52374.
Damiola et al. Breast Cancer Research 2014, 16:R58 Page 15 of 16
http://breast-cancer-research.com/content/16/3/R5823. John EM, Hopper JL, Beck JC, Knight JA, Neuhausen SL, Senie RT, Ziogas A,
Andrulis IL, Anton-Culver H, Boyd N, Buys SS, Daly MB, O’Malley FP, Santella
RM, Southey MC, Venne VL, Venter DJ, West DW, Whittemore AS, Seminara
D: The Breast Cancer Family Registry: an infrastructure for cooperative
multinational, interdisciplinary and translational studies of the genetic
epidemiology of breast cancer. Breast Cancer Res 2004, 6:R375–R389.
24. Voegele C, Tavtigian SV, de Silva D, Cuber S, Thomas A, Le Calvez-Kelm F:
A Laboratory Information Management System (LIMS) for a high through-
put genetic platform aimed at candidate gene mutation screening.
Bioinformatics 2007, 23:2504–2506.
25. Nguyen-Dumont T, Calvez-Kelm FL, Forey N, McKay-Chopin S, Garritano S,
Gioia-Patricola L, De Silva D, Weigel R, Sangrajrang S, Lesueur F, Tavtigian
SV: Description and validation of high-throughput simultaneous
genotyping and mutation scanning by high-resolution melting curve
analysis. Hum Mutat 2009, 30:884–890.
26. Garritano S, Gemignani F, Voegele C, Nguyen-Dumont T, Le Calvez-Kelm F,
De Silva D, Lesueur F, Landi S, Tavtigian SV: Determining the effectiveness
of High Resolution Melting analysis for SNP genotyping and mutation
scanning at the TP53 locus. BMC Genet 2009, 10:5.
27. The exome variant server. [http://evs.gs.washington.edu/EVS/]
28. 1000 Genomes. [http://browser.1000genomes.org/index.html]
29. T-Coffee. [http://www.tcoffee.org/]
30. Wallace IM, O’Sullivan O, Higgins DG, Notredame C: M-Coffee: combining
multiple sequence alignment methods with T-Coffee. Nucleic Acids Res
2006, 34:1692–1699.
31. Felsenstein J: PHYLIP - Phylogeny Inference Package (version 3.2).
Cladistics 1989, 5:164–166.
32. Align GVGD. [http://agvgd.iarc.fr]
33. Tavtigian SV, Byrnes GB, Goldgar DE, Thomas A: Classification of rare
missense substitutions, using risk surfaces, with genetic- and molecular-
epidemiology applications. Hum Mutat 2008, 29:1342–1354.
34. Kumar P, Henikoff S, Ng PC: Predicting the effects of coding non-
synonymous variants on protein function using the SIFT algorithm.
Nat Protoc 2009, 4:1073–1081.
35. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P,
Kondrashov AS, Sunyaev SR: A method and server for predicting
damaging missense mutations. Nat Methods 2010, 7:248–249.
36. Tavtigian SV, Greenblatt MS, Lesueur F, Byrnes GB: In silico analysis of
missense substitutions using sequence-alignment based methods.
Hum Mutat 2008, 29:1327–1336.
37. Yeo G, Burge CB: Maximum entropy modeling of short sequence
motifs with applications to RNA splicing signals. J Comput Biol 2004,
11:377–394.
38. Easton DF, Deffenbaugh AM, Pruss D, Frye C, Wenstrup RJ, Allen-Brady K,
Tavtigian SV, Monteiro AN, Iversen ES, Couch FJ, Goldgar DE: A systematic
genetic assessment of 1,433 sequence variants of unknown clinical
significance in the BRCA1 and BRCA2 breast cancer-predisposition
genes. Am J Hum Genet 2007, 81:873–883.
39. Vallee MP, Francy TC, Judkins MK, Babikyan D, Lesueur F, Gammon A,
Goldgar DE, Couch FJ, Tavtigian SV: Classification of missense
substitutions in the BRCA genes: a database dedicated to Ex-UVs.
Hum Mutat 2012, 33:22–28.
40. NGRL 1000 Genomes Variant Access. [https://secure.ngrl.org.uk/
1kg_querytool/]
41. Breast cancer information core. [http://research.nhgri.nih.gov/projects/bic/
index.shtml]
42. van Puijenbroek M, van Asperen CJ, van Mil A, Devilee P, van Wezel T,
Morreau H: Homozygosity for a CHEK2*1100delC mutation identified in
familial colorectal cancer does not lead to a severe clinical phenotype.
J Pathol 2005, 206:198–204.
43. Adank MA, Jonker MA, Kluijt I, van Mil SE, Oldenburg RA, Mooi WJ,
Hogervorst FB, van den Ouweland AM, Gille JJ, Schmidt MK, van der Vaart
AW, Meijers-Heijboer H, Waisfisz Q: CHEK2*1100delC homozygosity is
associated with a high breast cancer risk in women. J Med Genet 2011,
48:860–863.
44. Huijts PE, Hollestelle A, Balliu B, Houwing-Duistermaat JJ, Meijers CM,
Blom JC, Ozturk B, Krol-Warmerdam EM, Wijnen J, Berns EM, Martens JW,
Seynaeve C, Kiemeney LA, van der Heijden HF, Tollenaar RA, Devilee P,
van Asperen CJ: CHEK2*1100delC homozygosity in the Netherlands-
prevalence and risk of breast and lung cancer. Eur J Hum Genet 2013,
22:46–51.45. Bouwman P, van der Gulden H, van der Heijden I, Drost R, Klijn CN,
Prasetyanti P, Pieterse M, Wientjens E, Seibler J, Hogervorst FB, Jonkers J:
A high-throughput functional complementation assay for classification
of BRCA1 missense variants. Cancer Discov 2013, 3:1142–1155.
46. Usui T, Ohta T, Oshiumi H, Tomizawa J, Ogawa H, Ogawa T: Complex
formation and functional versatility of Mre11 of budding yeast in
recombination. Cell 1998, 95:705–716.
47. InterPro protein sequence analysis and classification. [http://www.ebi.ac.
uk/interpro/]
48. UniProt. [http://www.uniprot.org/]
49. NCBI conserved domains database. [http://www.ncbi.nlm.nih.gov/
Structure/cdd/cdd.shtml]
50. Marchler-Bauer A, Lu S, Anderson JB, Chitsaz F, Derbyshire MK, DeWeese-
Scott C, Fong JH, Geer LY, Geer RC, Gonzales NR, Gwadz M, Hurwitz DI,
Jackson JD, Ke Z, Lanczycki CJ, Lu F, Marchler GH, Mullokandov M,
Omelchenko MV, Robertson CL, Song JS, Thanki N, Yamashita RA, Zhang D,
Zhang N, Zheng C, Bryant SH: CDD: a Conserved Domain Database
for the functional annotation of proteins. Nucleic Acids Res 2011,
39:D225–D229.
51. Schiller CB, Lammens K, Guerini I, Coordes B, Feldmann H, Schlauderer F,
Mockel C, Schele A, Strasser K, Jackson SP, Hopfner KP: Structure of
Mre11-Nbs1 complex yields insights into ataxia-telangiectasia-like
disease mutations and DNA damage signaling. Nat Struct Mol Biol 2012,
19:693–700.
52. Hopfner KP, Karcher A, Craig L, Woo TT, Carney JP, Tainer JA: Structural
biochemistry and interaction architecture of the DNA double-strand
break repair Mre11 nuclease and Rad50-ATPase. Cell 2001, 105:473–485.
53. Williams RS, Moncalian G, Williams JS, Yamada Y, Limbo O, Shin DS,
Groocock LM, Cahill D, Hitomi C, Guenther G, Moiani D, Carney JP, Russell P,
Tainer JA: Mre11 dimers coordinate DNA end bridging and nuclease
processing in double-strand-break repair. Cell 2008, 135:97–109.
54. Lammens K, Bemeleit DJ, Mockel C, Clausing E, Schele A, Hartung S, Schiller
CB, Lucas M, Angermuller C, Soding J, Strasser K, Hopfner KP: The Mre11:
Rad50 structure shows an ATP-dependent molecular clamp in DNA
double-strand break repair. Cell 2011, 145:54–66.
55. Williams GJ, Williams RS, Williams JS, Moncalian G, Arvai AS, Limbo O,
Guenther G, SilDas S, Hammel M, Russell P, Tainer JA: ABC ATPase
signature helices in Rad50 link nucleotide state to Mre11 interface for
DNA repair. Nat Struct Mol Biol 2011, 18:423–431.
56. Lim HS, Kim JS, Park YB, Gwon GH, Cho Y: Crystal structure of the
Mre11-Rad50-ATPgammaS complex: understanding the interplay
between Mre11 and Rad50. Genes Dev 2011, 25:1091–1104.
57. Dery U, Coulombe Y, Rodrigue A, Stasiak A, Richard S, Masson JY:
A glycine-arginine domain in control of the human MRE11 DNA repair
protein. Mol Cell Biol 2008, 28:3058–3069.
58. Boisvert FM, Dery U, Masson JY, Richard S: Arginine methylation of MRE11
by PRMT1 is required for DNA damage checkpoint control. Genes Dev
2005, 19:671–676.
59. Hopfner KP, Karcher A, Shin DS, Craig L, Arthur LM, Carney JP, Tainer JA:
Structural biology of Rad50 ATPase: ATP-driven conformational control
in DNA double-strand break repair and the ABC-ATPase superfamily.
Cell 2000, 101:789–800.
60. Williams RS, Dodson GE, Limbo O, Yamada Y, Williams JS, Guenther G,
Classen S, Glover JN, Iwasaki H, Russell P, Tainer JA: Nbs1 flexibly tethers
Ctp1 and Mre11-Rad50 to coordinate DNA double-strand break
processing and repair. Cell 2009, 139:87–99.
61. Lloyd J, Chapman JR, Clapperton JA, Haire LF, Hartsuiker E, Li J, Carr AM,
Jackson SP, Smerdon SJ: A supramodular FHA/BRCT-repeat architecture
mediates Nbs1 adaptor function in response to DNA damage. Cell 2009,
139:100–111.
62. Falck J, Coates J, Jackson SP: Conserved modes of recruitment of ATM,
ATR and DNA-PKcs to sites of DNA damage. Nature 2005, 434:605–611.
63. You Z, Chahwan C, Bailis J, Hunter T, Russell P: ATM activation and its
recruitment to damaged DNA require binding to the C terminus of
Nbs1. Mol Cell Biol 2005, 25:5363–5379.
64. SIFT. [http://sift.jcvi.org/]
65. PolyPhen-2. [http://genetics.bwh.harvard.edu/pph2/]
66. di Masi A, Antoccia A: NBS1 heterozygosity and cancer risk. Curr Genomics
2008, 9:275–281.
67. di Masi A, Viganotti M, Polticelli F, Ascenzi P, Tanzarella C, Antoccia A:
The R215W mutation in NBS1 impairs gamma-H2AX binding and affects
Damiola et al. Breast Cancer Research 2014, 16:R58 Page 16 of 16
http://breast-cancer-research.com/content/16/3/R58DNA repair: molecular bases for the severe phenotype of 657del5/
R215W Nijmegen breakage syndrome patients. Biochem Biophys Res
Commun 2008, 369:835–840.
68. Dzikiewicz-Krawczyk A, Mosor M, Januszkiewicz D, Nowak J: Impact of
heterozygous c.657–661del, p.I171V and p.R215W mutations in NBN on
nibrin functions. Mutagenesis 2012, 27:337–343.
69. Delia D, Piane M, Buscemi G, Savio C, Palmeri S, Lulli P, Carlessi L, Fontanella
E, Chessa L: MRE11 mutations and impaired ATM-dependent responses
in an Italian family with ataxia-telangiectasia-like disorder. Hum Mol
Genet 2004, 13:2155–2163.
doi:10.1186/bcr3669
Cite this article as: Damiola et al.: Rare key functional domain missense
substitutions in MRE11A, RAD50, and NBN contribute to breast cancer
susceptibility: results from a Breast Cancer Family Registry case-control
mutation-screening study. Breast Cancer Research 2014 16:R58.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
